Drugs / Phloroglucin
Phloroglucin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03342118 | Sep → Dec 2017 | — | Keimyung University Dongsan Medical Center | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01842932 | Dec 2009 → Dec 2013 | — | Ajou University School of Medicine | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07184099 | Jan → Jun 2025 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06233643 Comparator | Feb 2024 | urinary tract obstruction | The Third Affiliated Hospital of Beijing University of Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Phloroglucin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03342118 ↗ |
| Known as | Flospan | “Phloroglucin(Flospan®) before endoscopy.” NCT03342118 ↗ |
| Known as | Phloroglucinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06233643 ↗ |
| Action | Inhibit | “Phloroglucin(Flospan®) prompts to release norepinephrine by impeding catecholamine O-methyl transferase enzymes in visceral smooth muscle” NCT03342118 ↗ |
| Route | Oral | “Phloroglucin (Flospan ®), which can be taken orally” NCT03342118 ↗ |